Endocrine Abstracts

Background: Neuroendocrine tumours (NET) are rare cancers arising from cells of the neuroendocrine system and frequently present with advanced disease. They are characterised by the presence of somatostatin receptors (SSTR) on the tumour surface. The presence of SSTR are associated with the inhibition of NET proliferation and have formed the basis of peptide receptor radionuclide therapy (PRRT), such as Lutathera. PRRT relies on SSTR tumour expression and patients without this...